RU95119831A - RISPERIDONPMOAT - Google Patents

RISPERIDONPMOAT

Info

Publication number
RU95119831A
RU95119831A RU95119831/04A RU95119831A RU95119831A RU 95119831 A RU95119831 A RU 95119831A RU 95119831/04 A RU95119831/04 A RU 95119831/04A RU 95119831 A RU95119831 A RU 95119831A RU 95119831 A RU95119831 A RU 95119831A
Authority
RU
Russia
Prior art keywords
composition according
compound according
compound
composition
risperidone
Prior art date
Application number
RU95119831/04A
Other languages
Russian (ru)
Other versions
RU2131428C1 (en
Inventor
Луи Месенс Жан
Пэтерс Йозеф
Original Assignee
Жансен Фармасетика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Жансен Фармасетика Н.В. filed Critical Жансен Фармасетика Н.В.
Priority claimed from PCT/EP1994/001296 external-priority patent/WO1994025460A1/en
Publication of RU95119831A publication Critical patent/RU95119831A/en
Application granted granted Critical
Publication of RU2131428C1 publication Critical patent/RU2131428C1/en

Links

Claims (1)

1. Соединение, являющееся солью присоединения памоиновой кислоты к рисперидону.1. A compound that is a salt of addition of pamoic acid to risperidone. 2. Рисперидонпамоат по п. 1 формулы I
Figure 00000001

3. Композиция, содержащая фармацевтически приемлемый носитель и в качестве активного средства фармацевтически эффективное количество соединения по п. 1.2. Risperidone according to claim 1 of formula I
Figure 00000001

3. A composition comprising a pharmaceutically acceptable carrier and, as an active agent, a pharmaceutically effective amount of a compound according to claim 1. 4. Композиция по п. 3 в лекарственной форме, пригодной для инъекций. 4. The composition according to claim 3 in a dosage form suitable for injection. 5. Композиция по п. 4 в виде водной суспензии. 5. The composition according to p. 4 in the form of an aqueous suspension. 6. Композиция по п. 5, дополнительно содержащая бензиловый спирт, сложный эфир сорбитана и воду. 6. The composition according to claim 5, further comprising benzyl alcohol, sorbitan ester and water. 7. Композиция по п. 6, дополнительно содержащая производное целлюлозы. 7. The composition according to p. 6, optionally containing a derivative of cellulose. 8. Способ получения композиции по п. 3, отличающийся тем, что фармацевтически эффективное количество соединения по п. 1 тщательно смешивают с фармацевтически приемлемым носителем. 8. The method for preparing the composition according to claim 3, wherein the pharmaceutically effective amount of the compound according to claim 1 is thoroughly mixed with a pharmaceutically acceptable carrier. 9. Соединение по п. 1 в качестве лекарственного средства. 9. The compound according to claim 1 as a drug. 10. Способ получения соединения по п. 1, отличающийся тем, что 3-/2-/4-(6-фтор-1,2-бензизоксазол-3-ил)-1-пиперидинил/этил/-6,7,8,9- тетрагидро-2-метил-4Н-пиридо/1,2-а/пиримидин-4-он обрабатывают памоиновой кислотой в инертном растворителе. 10. A method of producing a compound according to claim 1, wherein 3- / 2- / 4- (6-fluoro-1,2-benzisoxazol-3-yl) -1-piperidinyl / ethyl / -6,7,8 , 9-tetrahydro-2-methyl-4H-pyrido / 1,2-a / pyrimidin-4-one is treated with pamoic acid in an inert solvent.
RU95119831A 1993-04-28 1994-04-22 Risperidone pamoate, method of its synthesis, antipsychotic composition on its base and method of its preparing RU2131428C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93201216.4 1993-04-28
EP93201216 1993-04-28
PCT/EP1994/001296 WO1994025460A1 (en) 1993-04-28 1994-04-22 Risperidone pamoate

Publications (2)

Publication Number Publication Date
RU95119831A true RU95119831A (en) 1997-11-10
RU2131428C1 RU2131428C1 (en) 1999-06-10

Family

ID=8213799

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95119831A RU2131428C1 (en) 1993-04-28 1994-04-22 Risperidone pamoate, method of its synthesis, antipsychotic composition on its base and method of its preparing

Country Status (32)

Country Link
US (2) US5612346A (en)
EP (1) EP0697019B1 (en)
JP (1) JP3478397B2 (en)
KR (1) KR100307101B1 (en)
CN (1) CN1041727C (en)
AT (1) ATE163418T1 (en)
AU (1) AU675136B2 (en)
BG (1) BG62004B1 (en)
CA (1) CA2160366C (en)
CY (1) CY2107B1 (en)
CZ (1) CZ286688B6 (en)
DE (1) DE69408666T2 (en)
DK (1) DK0697019T3 (en)
ES (1) ES2113652T3 (en)
FI (1) FI109125B (en)
GR (1) GR3026028T3 (en)
HK (1) HK1006059A1 (en)
HU (1) HU218212B (en)
IL (1) IL109448A (en)
LV (1) LV12315B (en)
NO (1) NO305083B1 (en)
NZ (1) NZ266143A (en)
PH (1) PH30476A (en)
PL (1) PL182466B1 (en)
RO (1) RO115955B1 (en)
RU (1) RU2131428C1 (en)
SG (1) SG47046A1 (en)
SI (1) SI9420031B (en)
SK (1) SK280589B6 (en)
TW (1) TW376319B (en)
WO (1) WO1994025460A1 (en)
ZA (1) ZA942909B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236700T3 (en) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-MICROENCAPSULATED BENZAZOLS.
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
CZ300725B6 (en) * 1997-09-30 2009-07-29 Eli Lilly And Company 2-Methylthiene benzodiazepine formulation
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (en) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
BR9914156A (en) * 1998-09-30 2001-06-26 Lilly Co Eli Formulation of 2-methyl-thieno-benzodiazepine
CA2349700A1 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
FR2802101B1 (en) 1999-12-10 2003-02-28 Aventis Pharma Sa COMBINATION OF CYMEMAZINE AND AN ATYPICAL NEUROLEPTIC
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2004017975A1 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Stable aqueous solutions of risperidone and methods for their preparation
KR20040034996A (en) * 2002-10-18 2004-04-29 한미약품 주식회사 Improved method for the preparation of risperidone
WO2004094414A1 (en) * 2003-04-22 2004-11-04 Synthon B.V. Water soluble salts of risperidone
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
PL1675573T4 (en) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) * 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
AU2005209310B2 (en) * 2004-01-29 2011-01-06 Neuromolecular, Inc. Combination of a NMDA receptor antagonist and a MAO-inhibitor or a GADPH-inhibitor for the treatment of central nervous system-related conditions
ATE511512T1 (en) * 2005-01-05 2011-06-15 Lilly Co Eli OLANZAPIN PAMOATE DIHYDRATE
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
AR055099A1 (en) * 2005-07-28 2007-08-08 Alza Corp LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
JP2009508859A (en) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド Nanoparticulate aripiprazole formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
AU2008262545B2 (en) 2007-05-25 2013-12-05 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
ES2661037T3 (en) * 2007-07-31 2018-03-27 Otsuka Pharmaceutical Co., Ltd. Procedures for producing a suspension of aripiprazole and a lyophilized formulation
PT2234617T (en) * 2007-12-19 2021-05-18 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
ES2972387T3 (en) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising sorbitan esters
WO2012147035A1 (en) 2011-04-26 2012-11-01 Torrent Pharmaceuticals Limited Acid addition salts of risperidone and pharmaceutical compositions thereof
EP2827866B1 (en) * 2012-03-19 2023-05-03 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (en) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising glycerol ester
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
EP2833866B1 (en) 2012-04-04 2018-11-21 Intervet International B.V. Soft chewable pharmaceutical products
CN102659577B (en) * 2012-04-07 2014-07-02 安徽绩溪县徽煌化工有限公司 Preparation method of pamoic acid
ES2792149T3 (en) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Pharmaceutical Compositions Having Improved Storage Stability
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN106831594B (en) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 Clonidine embonate and preparation method thereof
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Similar Documents

Publication Publication Date Title
RU95119831A (en) RISPERIDONPMOAT
JP2744057B2 (en) Combination of pyrimidine and salicylic acid derivatives for inducing and stimulating hair growth and reducing hair loss
CA2011532C (en) Formulation
RU2131428C1 (en) Risperidone pamoate, method of its synthesis, antipsychotic composition on its base and method of its preparing
RU95118439A (en) IMIDAZOPIRIDINE AND METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD FOR ITS PRODUCTION
RU2003116060A (en) CARBAMIDE SUBSTITUTED IMIDAZOCHINOLINE ETHERS
RU95121639A (en) AZA Cyclohexappeptide Compounds
CA2284977A1 (en) 3,3-disubstituted propylamines, their use and preparation
RU2006101999A (en) MEANS FOR THE TREATMENT OF SCHIZOPHRENIA BASED ON HYDROGEN PYRIDO (4,3-B) INDOLES (OPTIONS), PHARMACOLOGICAL PRODUCT ON ITS BASIS AND METHOD OF ITS APPLICATION
ATE4903T1 (en) 1-, 6- AND 2- SUBSTITUTED 1-CARBA-2-PENEM-3CARBONS[URES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
RU96111026A (en) 7 - ([1A, 5A, 6A] -6-AMINO-3-AZABICYCLO [3.1.0.] HEX-3-IL) -6-fluoro-1- (2,4-difluorophenyl) -1,4-dihydro -4-OXO-1,8- NAPHTHIRIDINE-3-CARBONIC ACID, METHANESULPHIC ACID SALT, METHOD FOR PRODUCING IT, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
CN1210027C (en) Pharmaceutical compositions for ulcer
RU96120199A (en) IMMUNOSUPRESSIVE COMPOSITION CONTAINING CYCLOSPORIN AND METHOD FOR PRODUCING IT
NO940523L (en) New pyrazine derivatives
US5665384A (en) Oily capsules of ketoprofen
RU96119364A (en) DERIVATIVE BENZAMIDE, COMPOSITIONS CONTAINING SUPERIOR DERIVATIVE, AND THEIR APPLICATION
ATE55248T1 (en) DRUG COMBINATION.
IL83086A (en) Stable,injectable solutions of vincristine salts
NO175369C (en) Analogous Process for Preparing the Therapeutically Active Compound (S) -7- (3-Amino-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, an in vivo readily cleavable lower alkyl ester or a pharmaceutically acceptable salt
US4617306A (en) Pharmaceutical preparation comprising co-dergocrine and a calcium antagonist
KR880004810A (en) Peptic Ulcer Treatment
RU95119815A (en) AGENT, ACTING ON THE CENTRAL NERVOUS SYSTEM, METHOD FOR ITS OBTAINING AND CONTAINING ITS PHARMACEUTICAL COMPOSITIONS
TH12553B (en) Risperidone Pamoet
RU2002115270A (en) Compounds and method for treating pain
TH18739A (en) Risperidone Pamoet